AIDS and Behavior

, Volume 23, Issue 7, pp 1689–1697 | Cite as

Maternal Motivation to Take Preventive Therapy in Antepartum and Postpartum Among HIV-Positive Pregnant Women in South Africa: A Choice Experiment

  • Hae-Young Kim
  • David W. Dowdy
  • Neil A. Martinson
  • Deanna Kerrigan
  • Carrie Tudor
  • Jonathan Golub
  • John F. P. Bridges
  • Colleen F. HanrahanEmail author
Original Paper


HIV-positive pregnant women who are initiated on lifelong antiretroviral therapy (ART) and isoniazid preventive therapy (IPT) have lower adherence rates after delivery. We quantified maternal motivation to take preventive therapy before and after delivery among pregnant women newly diagnosed with HIV. We enrolled pregnant women (≥ 18 years) with a recent HIV diagnosis (< 6 months) at 14 public primary health clinics in Matlosana, South Africa and followed them in the postpartum period. Participants received eight choice tasks comparing two mutually exclusive sub-sets of seven possible benefits related to preventive therapy identified through literature reviews and key informant interviews. Data was analyzed using conditional logit regression in the antepartum versus postpartum periods. Coefficients are reported with 95% confidence intervals (CI). Sixty-five women completed surveys both at enrollment and in the postpartum period. All women were already on ART, while 21 (32%) were receiving IPT at enrollment. The mean CD4 count was 436 (± 246) cells/mm3. In the antepartum period, preventing HIV transmission to partners was the most important benefit (coefficients (ß) = 0.87, 95% CI 0.64, 1.11), followed by keeping healthy for family (ß = 0.75, 95% CI 0.52, 0.97). Such prioritization significantly decreased in the postpartum period (p < 0.001). Compared to other motivators, keeping a high CD4 count was least prioritized in the antepartum period (ß = 0.19, 95% CI − 0.04, 0.43) but was most prioritized in the postpartum period (ß = 0.39, 95% CI 0.21, 0.57). These results highlight that messages on family might be particularly salient in the antepartum period, and keeping CD4 count high in the postpartum period. Understanding maternal motivation may help to design targeted health promotion messages to HIV-positive women around the time of delivery.


Discrete choice experiment Isoniazid preventive therapy Antiretroviral therapy Pregnant women South Africa 



We thank all study participants for devoting their time to take part in this study. We thank our study coordinators, Sandy Chon, Cokiswa Quomfo, Juanita Market, Mmabatho Malegotsia, Elvis Rangxa, Thembekile Mmmoledi as well as all study staff who helped in data collection.

Author Contributions

All authors contributed to design the study. H-YK, CFH, and NM helped to collect the data. H-YK and JFPB performed the data analysis. DK and CT conducted the qualitative interviews. HYK wrote the initial draft of the paper. All authors contributed to read and revised the final manuscript.


This study was funded by NIH supplement R01AI095014 02S1.

Compliance with Ethical Standards

Conflict of interest

The authors declared that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva; 2011.Google Scholar
  2. 2.
    Idele P, Hayashi C, Porth T, Mamahit A, Mahy M. Prevention of mother-to-child transmission of HIV and paediatric HIV care and treatment monitoring: from measuring process to impact and elimination of mother-to-child transmission of HIV. AIDS Behav. 2017;21(S1):1–11.CrossRefGoogle Scholar
  3. 3.
    Gounder CR, Wada NI, Kensler C, Violari A, McIntyre J, Chaisson RE, et al. Active tuberculosis case-finding among pregnant women presenting to antenatal clinics in Soweto, South Africa. J Acquir Immune Defic Syndr. 2011;57(4):e77–84.CrossRefGoogle Scholar
  4. 4.
    Pillay T, Khan M, Moodley J. The increasing burden of tuberculosis in pregnant women, newborns and infants under 6 months of age in Durban, KwaZulu-Natal. South African. Med J. 2001;91(11):983–7.Google Scholar
  5. 5.
    Karim QA, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin Infect Dis. 2010;50(Suppl 3):S122–9.CrossRefGoogle Scholar
  6. 6.
    Department of Health Republic of South Africa. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. 2015.Google Scholar
  7. 7.
    World Health Organization. Global Tuberculosis Report 2017. Geneva; 2017.Google Scholar
  8. 8.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefGoogle Scholar
  9. 9.
    Clouse K, Schwartz S, Van Rie A, Bassett J, Yende N, Pettifor A. What they wanted was to give birth; nothing else. J Acquir Immune Defic Syndr. 2014;67(1):e12–8.CrossRefGoogle Scholar
  10. 10.
    Clouse K, Pettifor A, Shearer K, Maskew M, Bassett J, Larson B, et al. Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Heal. 2013;18(4):451–60.CrossRefGoogle Scholar
  11. 11.
    Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis. 2005;9(3):263–9.Google Scholar
  12. 12.
    Golub J, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631–6.CrossRefGoogle Scholar
  13. 13.
    Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012;26(16):2039–52.CrossRefGoogle Scholar
  14. 14.
    Tiam A, Machekano R, Gounder CR, Maama-maime LBM, Ntene-sealiete K, Sahu M, et al. Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy. J Acquir Immune Defic Syndr. 2014;67(1):e5–11.CrossRefGoogle Scholar
  15. 15.
    Reda AA, Biadgilign S. Determinants of adherence to antiretroviral therapy among HIV-infected patients in Africa. AIDS Res Treat. 2012;2012:574656.Google Scholar
  16. 16.
    Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, Peyramond D, et al. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr. 2006;41(4):477–85.CrossRefGoogle Scholar
  17. 17.
    Holtzman C, Brady K, Yehia B. Retention in care and medication adherence: current challenges to antiretroviral therapy success. Drugs. 2015;75(5):445–54.CrossRefGoogle Scholar
  18. 18.
    Bridges J, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Heal. 2011;14(4):403–13.CrossRefGoogle Scholar
  19. 19.
    Louviere J, Hensher D, Swait J. Stated Choice Methods: Analysis and Applications. Cambridge: Cambridges University Press; 2000.CrossRefGoogle Scholar
  20. 20.
    Golub J, Lebina L, Qomfu C, Chon S, Cohn S, Masonoke K, et al. Implementation of QuantiFERON®– TB Gold In-Tube test for diagnosing latent tuberculosis among newly diagnosed HIV-infected patients in South Africa. In: In: 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union). Cape Town, South Africa; 2015. p. [Abstract OA-399-05].Google Scholar
  21. 21.
    Kerrigan D, Tudor C, Motlhaoleng K, Lebina L, Qomfu C, Variava E, et al. Relevance and acceptability of using the Quantiferon gold test (QGIT) to screen CD4 blood draws for latent TB infection among PLHIV in South Africa: formative qualitative research findings from the TEKO trial. BMC Health Serv Res. 2018;18(1):288.CrossRefGoogle Scholar
  22. 22.
    Carballo-Diéguez A, Stein Z, Sáez H, Dolezal C, Nieves-Rosa L, Díaz F. Frequent use of lubricants for anal sex among men who have sex with men: the HIV prevention potential of a microbicidal gel. Am J Public Health. 2000;90(7):1117–21.CrossRefGoogle Scholar
  23. 23.
    Newman PA, Cameron MP, Roungprakhon S, Tepjan S, Scarpa R. Acceptability and preferences for hypothetical rectal microbicides among a community sample of young men who have sex with men and transgender women in Thailand: a discrete choice experiment. AIDS Behav. 2016;20(11):2588–601.CrossRefGoogle Scholar
  24. 24.
    Kruk ME, Paczkowski M, Mbaruku G, de Pinho H, Galea S. Women’s preferences for place of delivery in rural Tanzania: a population-based discrete choice experiment. Am J Public Health. 2009;99(9):1666–72.CrossRefGoogle Scholar
  25. 25.
    Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS ONE. 2014;9(2):e88166.CrossRefGoogle Scholar
  26. 26.
    Faal M, Naidoo N, Glencross DK, Venter WDF, Osih R. Providing immediate CD4 count results at HIV testing improves ART initiation. J Acquir Immune Defic Syndr. 2011;58(3):e54–9.CrossRefGoogle Scholar
  27. 27.
    Sutton R, Lahuerta M, Abacassamo F, Ahoua L, Tomo M, Lamb MR, et al. Feasibility and acceptability of health communication interventions within a combination intervention strategy for improving linkage and retention in HIV care in Mozambique. J Acquir Immune Defic Syndr. 2017;74(Suppl 1):S29–36.CrossRefGoogle Scholar
  28. 28.
    Zuch M, Lurie M. “A virus and nothing else”: the effect of ART on HIV-related stigma in rural South Africa. AIDS Behav. 2012;16(3):564–70.CrossRefGoogle Scholar
  29. 29.
    Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task. Value Heal. 2013;16(1):3–13.CrossRefGoogle Scholar
  30. 30.
    Montgomery DC. Design and analysis of experiments. Hoboken: Wiley; 2017.Google Scholar
  31. 31.
    Orme B. Getting started with conjoint analysis: strategies for product design and pricing research. Madison: Research Publishers LLC; 2006.Google Scholar
  32. 32.
    de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373–84.CrossRefGoogle Scholar
  33. 33.
    de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145–72.CrossRefGoogle Scholar
  34. 34.
    Ryan M, Major K, Skåtun D. Using discrete choice experiments to go beyond clinical outcomes when evaluating clinical practice. J Eval Clin Pract. 2005;11(4):328–38.CrossRefGoogle Scholar
  35. 35.
    Hauber AB, González JM, Groothuis-Oudshoorn CGM, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Heal. 2016;19(4):300–15.CrossRefGoogle Scholar
  36. 36.
    Black S, Zulliger R, Marcus R, Mark D, Myer L, Bekker L-G. Acceptability and challenges of rapid ART initiation among pregnant women in a pilot programme, Cape Town, South Africa. AIDS Care. 2014;26(6):736–41.CrossRefGoogle Scholar
  37. 37.
    Lake Snell Perry & Associates Inc. The healthcare experiences of women with HIV/AIDS: Insights from focus groups. Henry Kaiser Family Foundation. 2003.Google Scholar
  38. 38.
    Kruk ME, Riley PL, Palma AM, Adhikari S, Ahoua L, Arnaldo C, et al. How can the health system retain women in HIV treatment for a lifetime? a discrete choice experiment in Ethiopia and Mozambique. PLoS ONE. 2016;11(8):e0160764.CrossRefGoogle Scholar
  39. 39.
    Penn C, Watermeyer J, Evans M. Why don’t patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS. Patient Educ Couns. 2011;83(3):310–8.CrossRefGoogle Scholar
  40. 40.
    Loggerenberg F, Gray D, Gengiah S, Kunene P, Gengiah TN, Naidoo K, et al. A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa. AIDS Patient Care STDS. 2015;29(5):299–306.CrossRefGoogle Scholar
  41. 41.
    Department of Health Republic of South Africa. One Year of Operation: A Case Study Mom Connect. 2015.Google Scholar
  42. 42.
    Kim HY, Dowdy DW, Martinson NA, Golub E, Bridges JFP, Hanrahan CF. Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a best-worst scaling survey. J Int AIDS Soc. 2018;21(7):e25143.CrossRefGoogle Scholar
  43. 43.
    Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12(3):255–66.CrossRefGoogle Scholar
  44. 44.
    Dal Fabbro MMFJ, da Cunha RV, Paniago AMM, Lindenberg ADSC, De Freitas GMB, Nogueira SA. Prospective study on the prevention of vertical transmission of HIV in Campo Grande, Mato Grosso do Sul, Brazil, from 1996 to 2001. Braz J Infect Dis. 2005;9(1):20–7.CrossRefGoogle Scholar
  45. 45.
    Franco M, Diego R, Claudio A, Giampietro G, Giampaolo Q, Gary Antezana C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3(5):371–8.CrossRefGoogle Scholar
  46. 46.
    Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, et al. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care. 2008;20(8):958–68.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Hae-Young Kim
    • 1
    • 2
    • 3
  • David W. Dowdy
    • 1
    • 4
  • Neil A. Martinson
    • 5
    • 6
  • Deanna Kerrigan
    • 4
    • 7
  • Carrie Tudor
    • 8
  • Jonathan Golub
    • 1
    • 4
    • 6
  • John F. P. Bridges
    • 4
    • 7
    • 9
  • Colleen F. Hanrahan
    • 1
    Email author
  1. 1.Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Africa Health Research InstituteKwazulu-NatalSouth Africa
  3. 3.School of Nursing and Public HealthUniversity of KwaZulu-NatalKwazulu-NatalSouth Africa
  4. 4.Department of International HealthJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  5. 5.Perinatal HIV Research UnitUniversity of WitwatersrandJohannesburgSouth Africa
  6. 6.Center for Tuberculosis ResearchJohns Hopkins UniversityBaltimoreUSA
  7. 7.Department of Health Behavior and SocietyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  8. 8.International Council of NursesGenevaSwitzerland
  9. 9.Department of Health Policy and ManagementJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations